Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people wi...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of psychiatry Vol. 191; no. 1; pp. 14 - 22
Main Authors Davies, Linda M., Lewis, Shôn, Jones, Peter B., Barnes, Thomas R. E., Gaughran, Fiona, Hayhurst, Karen, Markwick, Alison, Lloyd, Helen
Format Journal Article
LanguageEnglish
Published Cambridge, UK Cambridge University Press 01.07.2007
RCP
Subjects
Adult
Antipsychotic Agents - economics
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Atypical
Cost analysis
Cost effectiveness
Cost-Benefit Analysis
Female
First generation
Health care expenditures
Health status
Humans
Male
Mental disorders
Patients
Pharmaceutical industry
Prescription drugs
Psychiatry
Psychosis
Psychotropic drugs
Quality of life
Quality-Adjusted Life Years
Randomized controlled trials
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - economics
Second generation
Sensitivity analysis
Statistics as Topic
Substance abuse treatment
United Kingdom
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice. Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective. The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-News-2
ObjectType-Feature-3
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.bp.106.028654